2473-9529

Blood Advances

American Society of Hematology

Health Score

0 Good

Metadata coverage

Abstract
ORCID
References
License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder
Award / grant

Affiliation & institutional identifiers

Affiliation
ROR ID

Update policy

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

1

Add license metadata to 5267 records

License metadata tells indexers and readers how each article may be reused.

High impact5267 DOIs
2

Add abstracts to 1347 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact1347 DOIs
3

Attach ORCID iDs across 919 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Low impact919 DOIs

DOIs for this ISSN

Showing the top 5 of 6124 DOIs, ordered by correction priority.

# Title Missing Priority Citations
1 Lyman GH, Carrier M, Ay C, et al. American Society of Hemato… (10.1182/bloodadvances.2021004734)
Abstract References ORCID License
173.24 53
2 ITP and thrombosis: an intriguing association (10.1182/bloodadvances.2017007989)
Abstract References ORCID License
153.15 33
3 American Society of Hematology 2018 guidelines for managemen… (10.1182/bloodadvances.2018022954)
ORCID License
141.53 676
4 Analysis of carfilzomib cardiovascular safety profile across… (10.1182/bloodadvances.2017015545)
Abstract ORCID License
141.49 76
5 American Society of Hematology 2018 guidelines for managemen… (10.1182/bloodadvances.2018024489)
ORCID License
140.85 655
6 Neunert C, Terrell DR, Arnold DM, et al. American Society of… (10.1182/bloodadvances.2019001380)
Abstract References ORCID License
139.79 24
7 Platelets as immune-sensing cells (10.1182/bloodadvances.2016000067)
Abstract ORCID License
133.36 59
8 Building a network for hemophilia care in China: 15 years of… (10.1182/bloodadvances.2019gs121524)
Abstract References ORCID License
130.10 19
9 Improving access to hemophilia care in sub-Saharan Africa by… (10.1182/bloodadvances.2019gs121537)
Abstract References ORCID License
130.10 19
10 Epidemiology of AL amyloidosis: a real-world study using US… (10.1182/bloodadvances.2018016402)
ORCID License
127.51 354
11 COVID-19 coagulopathy vs disseminated intravascular coagulat… (10.1182/bloodadvances.2020002197)
Abstract References License
126.76 48
12 Prolonged thrombocytopenia after CAR T-cell therapy: the rol… (10.1182/bloodadvances.2022008066)
Abstract ORCID License
126.76 48
13 Increasing hydroxyurea use in children with sickle cell dise… (10.1182/bloodadvances.2018gs110347)
Abstract References ORCID License
123.04 16
14 Targeted deep sequencing in polycythemia vera and essential… (10.1182/bloodadvances.2016000216)
ORCID License
121.97 274
15 Recent trends in multiple myeloma incidence and survival by… (10.1182/bloodadvances.2016002493)
ORCID License
121.49 268
16 Thrombotic thrombocytopenic purpura: diagnostic criteria, cl… (10.1182/bloodadvances.2017005124)
ORCID License
120.16 252
17 Effects of daratumumab on natural killer cells and impact on… (10.1182/bloodadvances.2017006866)
ORCID License
116.82 216
18 Pharmacologic control of CAR-T cell function using dasatinib (10.1182/bloodadvances.2018028720)
ORCID License
116.82 216
19 Targeted deep sequencing in primary myelofibrosis (10.1182/bloodadvances.2016000208)
ORCID License
115.37 202
20 Evolution, trends, outcomes, and economics of hematopoietic… (10.1182/bloodadvances.2017010041)
ORCID License
114.61 195
21 Establishing care for sickle cell disease in western Kenya:… (10.1182/bloodadvances.2019gs121620)
Abstract References ORCID License
114.61 13
22 First case of COVID-19 in a patient with multiple myeloma su… (10.1182/bloodadvances.2020001907)
ORCID License
114.61 195
23 Third-party fecal microbiota transplantation following allo-… (10.1182/bloodadvances.2018017731)
ORCID License
114.28 192
24 US intergroup study of chemotherapy plus dasatinib and allog… (10.1182/bloodadvances.2016001495)
ORCID License
113.36 184
25 Clinical efficacy of anakinra to mitigate CAR T-cell therapy… (10.1182/bloodadvances.2020002328)
Abstract License
113.36 184
26 Phase 1 investigation of lenalidomide/rituximab plus outcome… (10.1182/bloodadvances.2017014845)
ORCID License
112.76 179
27 Clinical consequences of clonal hematopoiesis of indetermina… (10.1182/bloodadvances.2018020222)
ORCID License
112.03 173
28 Capacity building: a novel pediatric hematology-oncology fel… (10.1182/bloodadvances.2018gs112742)
Abstract References ORCID License
111.39 12
29 A CD123-targeting antibody-drug conjugate, IMGN632, designed… (10.1182/bloodadvances.2018017517)
ORCID License
110.87 164
30 BCR-ABL + acute myeloid leukemia: are we always de… (10.1182/bloodadvances.2018015594)
Abstract ORCID License
109.68 28
31 Comparative effectiveness of direct oral anticoagulants and… (10.1182/bloodadvances.2017010694)
ORCID License
109.66 155
32 Platelet transfusions improve hemostasis and survival in a s… (10.1182/bloodadvances.2018017699)
ORCID License
109.38 153
33 Cumulative incidence, risk factors, and management of atrial… (10.1182/bloodadvances.2017009720)
ORCID License
108.66 148
34 Characterizing the O-glycosylation landscape of human plasma… (10.1182/bloodadvances.2016002121)
ORCID License
108.22 145
35 Evaluating measurable residual disease in acute myeloid leuk… (10.1182/bloodadvances.2018016378)
ORCID License
108.07 144
36 Hypomethylating agents in relapsed and refractory AML: outco… (10.1182/bloodadvances.2018016121)
ORCID License
106.36 133
37 A next-generation sequencing–based assay for minimal residua… (10.1182/bloodadvances.2018015925)
ORCID License
106.03 131
38 Inotuzumab ozogamicin in adults with relapsed or refractory… (10.1182/bloodadvances.2016001925)
ORCID License
104.50 122
39 Mature murine megakaryocytes present antigen-MHC class I mol… (10.1182/bloodadvances.2017007021)
ORCID License
104.32 121
40 Misdiagnosis of primary immune thrombocytopenia and frequenc… (10.1182/bloodadvances.2017010942)
ORCID License
104.32 121
41 Enhanced liver gene transfer and evasion of preexisting humo… (10.1182/bloodadvances.2017010181)
ORCID License
104.14 120
42 The use of immunosuppressive therapy in MDS: clinical outcom… (10.1182/bloodadvances.2018019414)
ORCID License
104.14 120
43 Sustained prothrombotic changes in COVID-19 patients 4 month… (10.1182/bloodadvances.2020003968)
Abstract License
103.59 117
44 Increasing rate of pulmonary embolism diagnosed in hospitali… (10.1182/bloodadvances.2017013292)
ORCID License
103.22 115
45 Novel approach to genetic analysis and results in 3000 hemop… (10.1182/bloodadvances.2016002923)
ORCID License
102.85 113
46 MRD detection in multiple myeloma: comparison between MSKCC… (10.1182/bloodadvances.2016003715)
ORCID License
102.46 111
47 Severe platelet dysfunction in NHL patients receiving ibruti… (10.1182/bloodadvances.2017011999)
ORCID License
102.46 111
48 161533 TriKE stimulates NK-cell function to overcome myeloid… (10.1182/bloodadvances.2017012369)
ORCID License
102.27 110
49 PTCy-based haploidentical vs matched related or unrelated do… (10.1182/bloodadvances.2018027748)
ORCID License
102.27 110
50 Activated neutrophils exert myeloid-derived suppressor cell… (10.1182/bloodadvances.2019031609)
ORCID License
102.27 110